A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.
Angiotensin-Converting Enzyme 2
Antibodies, Monoclonal
/ pharmacology
Antibodies, Neutralizing
/ pharmacology
Antibodies, Viral
/ pharmacology
Betacoronavirus
/ drug effects
COVID-19
Coronavirus Infections
Drug Design
Drug Discovery
Humans
Pandemics
Peptidyl-Dipeptidase A
/ drug effects
Pneumonia, Viral
Recombinant Proteins
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ drug effects
Biparatopic
COVID-19
SARS-CoV-2
antibody-ACE2 fusion
neutralizing antibody
Journal
mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829
Informations de publication
Date de publication:
Historique:
entrez:
18
8
2020
pubmed:
18
8
2020
medline:
28
8
2020
Statut:
ppublish
Résumé
In the absence of a proven effective vaccine preventing infection by SARS-CoV-2, or a proven drug to treat COVID-19, the positive results of passive immune therapy using convalescent serum provide a strong lead. We have developed a new class of tetravalent, biparatopic therapy, 89C8-ACE2. It combines the specificity of a monoclonal antibody (89C8) that recognizes the relatively conserved N-terminal domain of the viral Spike (S) glycoprotein, and the ectodomain of ACE2, which binds to the receptor-binding domain of S. This molecule shows exceptional performance
Identifiants
pubmed: 32804015
doi: 10.1080/19420862.2020.1804241
pmc: PMC7531490
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Neutralizing
0
Antibodies, Viral
0
Recombinant Proteins
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Peptidyl-Dipeptidase A
EC 3.4.15.1
ACE2 protein, human
EC 3.4.17.23
Angiotensin-Converting Enzyme 2
EC 3.4.17.23
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1804241Références
J Immunol. 2011 Jun 15;186(12):7264-8
pubmed: 21576510
Science. 2020 Aug 7;369(6504):650-655
pubmed: 32571838
F1000Res. 2020 Jan 31;9:72
pubmed: 32117569
EMBO J. 2005 Apr 20;24(8):1634-43
pubmed: 15791205
Int J Environ Res Public Health. 2020 Mar 03;17(5):
pubmed: 32138266
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
J Biomol Screen. 2016 Jan;21(1):88-95
pubmed: 26442912
Nat Med. 2005 Aug;11(8):875-9
pubmed: 16007097
PLoS Pathog. 2012;8(8):e1002859
pubmed: 22876187
Emerg Infect Dis. 2007 Oct;13(10):1562-4
pubmed: 18258008
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Expert Opin Biol Ther. 2009 Mar;9(3):355-68
pubmed: 19216624
Cell. 2020 May 28;181(5):1004-1015.e15
pubmed: 32375025
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
J Gen Virol. 1986 Dec;67 ( Pt 12):2803-6
pubmed: 2432166
MAbs. 2020 Jan-Dec;12(1):e1782600
pubmed: 32546047
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Bull World Health Organ. 1969;40(1):113-21
pubmed: 4183812
Nat Commun. 2020 Mar 27;11(1):1620
pubmed: 32221306
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Virology. 2009 Nov 10;394(1):39-46
pubmed: 19748648